Adults 18 to 80, any sex, with Ischemia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Comparison of Accuracy of ReSTE Imaging to SPECT Imaging in Diagnosis of IschemiaPrimary· 1 day
As primary analysis, paired test of equivalence used for proportions proposed by Tango to test equivalence of the two ischemia tests among tSPECT positive patients.
Positive RESTE proportion with positive angiogram
Group
Value
95% CI
Experimental: ReSTE Cardiac Imaging
0.1538
0.0151 – 0.2925
Positive nuclear stress test proportion with positive angiogram
Group
Value
95% CI
Experimental: ReSTE Cardiac Imaging
0.2308
0.0688 – 0.3928
Cardiac Event Rates After ReSTE and SPECT ImagingSecondary· 30 days
Cardiac events after ReSTE and SPECT imaging included myocardial infarction,heart failure, sudden cardiac death, cerebrovascular accident
Group
Value
95% CI
Experimental: ReSTE Cardiac Imaging
0
Sponsor's own description
The goal of this clinical research study is to compare regadenoson nuclear stress testing with echocardiography strain measurements (an ultrasound imaging method that measures hearts function) in detecting coronary artery disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT03505736 — Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
· completed
Other recruiting trials for Ischemia
Currently open trials in the same condition.
NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
· recruiting
NCT05487820 — Detecting Tissue Ischemia in Reconstruction Flaps by a Novel CO2 Biosensor (DIMENSION-study)
· NA
· recruiting
NCT05297266 — Early Discovery of Ischemia After Replantation Surgery of the Extremities
· NA
· recruiting
NCT05333068 — COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events
· NA
· active not recruiting
NCT04924985 — Goal-directed CPR Using Cerebral Oximetry
· NA
· active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem
· Phase 1, PHASE2
· not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and
· Phase 1
· not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che
· Phase 2
· not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca
· Phase 2
· not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar
· Phase 1
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 2 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02130453.